Testing effectiveness (Phase 2)Ended earlyNCT03094611
What this trial is testing
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
Who this might be right for
CD22 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center 4